Not wanting to break a winning streak, Clarient delivered its 16th consecutive quarter of quarterly revenue growth. The company posted revenues of $16.9 million in its most recent quarter, a 71% increase […]
Global Cancer Consortium
Rapture: AngioDynamics’ Lung Cancer Treatment Shows Promise
Back in 2004, shares of Rita Medical surged as much as 67 percent after it reported positive results for its radio-frequency ablation (RFA) technology in a trial of lung cancer patients. The […]
[Quick Take] Interview with Vijay Aggarwal, CEO of Aureon Laboratories
Aureon Laboratories is developing predictive and personalized cancer treatment options. Aureon employs a unique ‘systems pathology’ approach to provide personalized test results by analyzing a patient’s existing biopsy sample using molecular diagnostics, […]
Inovio Biomedical and VGX Pharmaceuticals to Merge
Citing synergies, Inovio Biomedical and VGX Pharmaceuticals have announced merger plans. Inovio’s electroporation technology uses brief, controlled electrical pulses to increase cellular uptake of gene expression in DNA-based treatments; this enhances the […]
[Quick Take] Interview with Gary Levine, CFO of Bostwick Laboratories
Bostwick Laboratories is a full-service laboratory specializing in uropathology. The company’s pathologists specialize in the diagnosis, treatment and subsequent management of prostate cancer, kidney disease, cancer of the bladder and other urologic […]
Clinical Study Brings iCAD’s Colon CAD Closer to Market
Colon cancer is among the most preventable cancers when caught early. More than 82 million Americans are eligible for colorectal cancer screening. Currently, diagnostics are underutilized due in part to the invasive […]
[Quick Take] Interview with William Oravan, Medical Director at Maple Leaf HIFU Co.
Maple Leaf HIFU Co. offers Ablatherm High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer. During the procedure, a probe is placed into the rectum after spinal or epidural anesthesia has […]
Bitter Ally Buys Bankrupt Immunicon
Veridex, LLC, a subsidiary of Johnson & Johnson, will acquire Immunicon for $31 million in cash. Immunicon filed for bankruptcy on Wednesday; the announcement sent shares tumbling to from $.27 to $.09. […]
